BioWorld

Feb. 15, 2007

Halozyme Getting Up To $65M From Expanded Baxter Alliance

Halozyme Therapeutics Inc. significantly expanded its relationships with Baxter Healthcare Corp., continuing momentum at the company that gained full steam two months ago. (BioWorld Today) Read More

Record Genzyme Revenues Clipped By AnorMED Buyout

Planning Pivotal MyoCell Trial, Bioheart Files For $35M IPO

Aging U.S. Population Is Fertile Ground For New Therapies

Current Orthopedic Strategies Complemented By Gene Therapy

GW Partners Sativex With Otsuka In Potential $273M Deal

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 21, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...